CLINICAL TRIALS
Use this page to search for clinical trials.
Gastrointestinal
Trial: NCT02563002
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High Colorectal Adenocarcinoma (KEYNOTE-177)
Click here for more information
This trial is available at:
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT01013649
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02368886
Disease Type: Gastrointestinal
Status: Open
Trial Information
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT01349881
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT01079780
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT01515787
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02664077
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT01793805
Disease Type: Gastrointestinal
Status: Open
Trial Information
NSABP Patient Registry and Biospecimen Profiling Repository
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02890355
Disease Type: Gastrointestinal
Status: Open
Trial Information
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02753127
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02921256
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02599324
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Click here for more information
This trial is available at:
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
For more information, please contact:
Trial: NCT02581215
Disease Type: Gastrointestinal
Status: Open
Trial Information
Phase II Randomized, Double-Blind Study of FOLFIRINOX plus Ramucirumab versus FOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
Click here for more information
This trial is available at:
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
For more information, please contact:
Trial: NCT02551991
Disease Type: Gastrointestinal
Status: Pending
Trial Information
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Click here for more information
This trial is available at:
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02776683
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Single Arm, Open-label, Multicenter, Multinational, Safety and Efficacy Phase IIIb Trial of BI 695502 Plus mFOLFOX6 in Patients With Previously Untreated Metastatic Colorectal Cancer
Click here for more information
This trial is available at:
Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
Trial: NCT02924376
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Click here for more information
This trial is available at:
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
For more information, please contact: